https://www.selleckchem.com/pr....oducts/vazegepant-hy
2 ± 6.1; women 54%; frailty phenotype 58%). The 6-month mortality and morbidity rates were 18% and 64%, respectively. The fit was good for both models (RMSEA and CFI = 0.029 [0.017-0.039] and 0.99 for Model 1, and 0.028 [0.017-0.039] and 0.99 for Model 2, respectively). Sarcopenia and cachexia were both directly and significantly associated with 6-month mortality (βsarcopenia = 0.18, p = 0.01; βcachexia = 0.52, p less then 0.0001) and morbidity (βsarcopenia = 0.37, p less then 0.0001; βcachexia = 0.19, p less then 0.02)
Curtir
Comentario
Compartilhar
